IOVS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ohguro, H.
Right arrow Articles by Nakazawa, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ohguro, H.
Right arrow Articles by Nakazawa, M.
(Investigative Ophthalmology and Visual Science. 2001;42:2589-2595.)
© 2001 by The Association for Research in Vision and Ophthalmology, Inc.

Retinal Dysfunction in Cancer-Associated Retinopathy Is Improved by Ca2+ Antagonist Administration and Dark Adaptation

Hiroshi Ohguro1, Kei-ichi Ogawa2, Tadao Maeda2, Ikuyo Maruyama1, Akiko Maeda2, Yoshiko Takano1 and Mitsuru Nakazawa1

1 From the Department of Ophthalmology, Hirosaki University School of Medicine, Japan; and the 2 Department of Ophthalmology, Sapporo Medical University School of Medicine, Japan.

PURPOSE. It was recently found that recoverin acts as an autoantigen recognized by sera of patients with cancer-associated retinopathy (CAR), and that CAR-like retinal dysfunction is produced by intravitreous administration of anti-recoverin antibody in Lewis rat eyes. To examine the pathologic molecular mechanism of CAR, and to elucidate an effective therapy for CAR, the function and morphology of CAR were compared with those of phototoxic retinal damage, another form of photoreceptor dysfunction, and the effect of nilvadipine, a Ca2+ antagonist, on the retinal degenerations was studied, using these models.

METHODS. Under different illumination conditions and/or medication with nilvadipine, the functional and morphologic properties of the retinas were evaluated after intravitreous injection of anti-recoverin antibody into Lewis rat eyes (six rats, 12 eyes in each experimental condition), using electroretinogram (ERG), rhodopsin phosphorylation, and light microscopy.

RESULTS. Anti-recoverin antibody administered into the vitreous of Lewis rat eyes induced a significant decrease and increase of ERG responses and rhodopsin phosphorylation levels, respectively, under cyclic or continuous light. Similar changes were observed in eyes of rats bred under continuous illumination that did not receive anti-recoverin antibodies. However, anti-recoverin antibody–induced retinal dysfunctions were not observed in rat eyes under dark conditions. Administration of nilvadipine, a Ca2+ antagonist, to the anti-recoverin antibody–treated rats and rats with phototoxic retinal dysfunction caused significant improvement of the deterioration of ERG and normalization of rhodopsin phosphorylation.

CONCLUSIONS. The present data indicate that anti-recoverin antibody–induced retinal dysfunction was functionally similar to phototoxic retinal dysfunction and was markedly suppressed under dark conditions or by systemic administration of a Ca2+ antagonist.




This article has been cited by other articles:


Home page
 IOVSHome page
F. Ishikawa, H. Ohguro, I. Ohguro, H. Yamazaki, K. Mamiya, T. Metoki, T. Ito, Y. Yokoi, and M. Nakazawa
Prolonged Rhodopsin Phosphorylation in Light-Induced Retinal Degeneration in Rat Models
Invest. Ophthalmol. Vis. Sci., December 1, 2006; 47(12): 5204 - 5211.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by the Association for Research in Vision and Ophthalmology